Keywords: amgen, files, enbrel, spondylitis, submitted, supplemental, biologics

Amgen files Enbrel for spondylitis

Article | 27 January 2003

Print This

Amgen has submitted a supplemental Biologics License Application withthe US Food and Drug Administration to expand the labeling of its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in